Summit Therapeutics Inc. (SMMT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Robert W. Duggan.
SMMT を有する IPO日 2015-03-05, 159 名の正社員, に上場 NASDAQ Global Market, 時価総額 $15.52B.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases in the United States and Latin America. The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic currently in Phase III clinical trials for Clostridioides difficile infection (CDI). Summit's pipeline also includes SMT-738, designed to address multidrug-resistant infections such as carbapenem-resistant Enterobacteriaceae, and the DDS-04 series for treating Enterobacteriaceae infections. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company is advancing its clinical programs to address critical unmet needs in infectious disease treatment.
